Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 2.57
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer,...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
Buy
Sell